JPMorgan upgrades biopharma stock to overweight on strong drug pipeline
A strong drug pipeline could boost shares of Ionis Pharmaceuticals in the future, JPMorgan says. Analyst Jessica Fye upgraded the biotech company, which develops human therapeutic drugs using antisense technology, to an overweight rating from neutral, and boosted her 12-month price her 12-month price target on the stock to $80 from $49. Shares of Ionis…